Boehringer Almirall News Today : Breaking News, Live Updates & Top Stories | Vimarsana

[co-authors:
On 4 March 2021, the European Commission (
Commission) opened a formal investigation into alleged anti-competitive conduct by the pharmaceutical company Teva. The Commission suspects Teva of having deployed a strategy with the intention of delaying the market entry of generic drugs that competed with Teva’s originator drug Copaxone. This may have amounted to an abuse of a dominant position prohibited under Art. 102 TFEU, the Commission states in its press release.
While the Commission has sanctioned patent settlements that delay the market entry of generic drugs (“pay-for-delay”) in a number of cases, with this new investigation, the Commission is exploring two novel “theories of harm”. The authority is concerned that Teva’s patent filing practices – namely the filing and selective withdrawal of divisional patents – and communication measures impeded the market entry of generic drugs. ....

United States , France General , United Kingdom , Roche Novartis , Margrethe Vestager , Agria Polska , Boehringer Almirall , European Commission , European Patent Office , Opposition Division , French Competition Authority , Allen Overy , While The Commission , Paris Court , European Court , French Supreme Court , Reckitt Benckiser , Gaviscon Original Liquid , General Court , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , ஒன்றுபட்டது கிஂக்டம் , ரோச் நோவர்த்திச் , ஐரோப்பிய தரகு , ஐரோப்பிய காப்புரிமை அலுவலகம் , எதிர்ப்பு பிரிவு ,